---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-008412"
form_type: "8-K"
ticker: "BBLG"
cik: "0001419554"
company_name: "Bone Biologics Corp"
filed_at: "2024-03-01T23:59:59+00:00"
generated_at: "2026-06-05T05:24:16.449514+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bone Biologics reports NB1 clinical trial progress: 3 sites engaged in Australia

## Summary
- NB1 pilot trial: 30 adults, randomized, evaluating safety & effectiveness in TLIF for DDD.
- Three Australian hospital sites engaged after HREC approval; study design reviewed by FDA.
- Inclusion: DDD at one level L2-S1, up to Grade 1 spondylolisthesis or retrolisthesis.
- Progress supports advancement toward potential US pivotal trial.

## SEC filing metadata
- accession: 0001493152-24-008412
- form_type: 8-K
- ticker: BBLG
- cik: 0001419554
- company_name: Bone Biologics Corp
- filed_at: 2024-03-01T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1419554/000149315224008412/0001493152-24-008412-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1419554/000149315224008412/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-008412
- JSON: https://secwatch.observer/filing/0001493152-24-008412.json
- Plain text: https://secwatch.observer/filing/0001493152-24-008412.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.